Cardiovascular disease (CVD) remains the number one cause of mortality among non-communicable diseases worldwide. In 2016, 1.83 million deaths were resulting from diseases of the circulatory system in the European Union, which was equivalent to 35.7% of all deaths; this is considerably higher than the second most prevalent cause of death, cancer. In Poland, CVD accounted for 168,280 deaths (43.3%) in that year (1). CVD occurs to be influenced by many factors over time. These are modifiable risk factors, such as high blood pressure, smoking, high cholesterol, unhealthy diet, obesity, type 2 diabetes, and physical inactivity or excessive alcohol consumption, and non-modifiable factors, such as family history, ethnicity, and age. A healthy lifestyle, awareness of the disease, or adherence to medication regimen remain a major concern. In such cases, the risk and/or incidence of CVD can be reduced by modification of risk factors as well as health education and optimization of pharmacotherapy. Undoubtedly, a community pharmacist can make a positive contribution in this process by improving the cardiovascular care of patients through interventions related to screening for the presence of risk factors, risk behavior counseling, and education, such as smoking cessation, monitoring of pharmacotherapy, and adherence (2).

In the US and some European countries, community pharmacists have long undertaken roles in both primary and secondary prevention and management of chronic diseases, such as CVD, that extend beyond the traditional dispensing of medicines. The concept of pharmaceutical care being defined as the responsible provision of pharmacotherapy for the purpose of achieving definite outcomes that improve a patient’s quality of life (3) was incorporated into Polish legislation in 2008. However such activities as patient’s referral or medication history taking were lacking before new regulations came into force in 2021, and this is not on par with the evolving role of community pharmacists in other parts of the world.
The activities which are core elements of pharmaceutical care provision, e.g. identification of drug-related problems within medication reviews and documentation of interventions, have been for months under public debate; it has borne fruit in novel law on the profession of the pharmacist (4).

On the other hand, the recent months of the COVID-19 pandemic crisis have brought new challenges for community pharmacists; besides their classic role as a source of medication. These have included maintaining infection control in the pharmacy and facilitating patient education regarding COVID-19 prevention products and medical equipment supplies. Polish pharmacists have been also at the frontline and remained open. They have become the first point of contact while access and availability to general practitioners were difficult. In that time community pharmacists have been permitted to prescribe Rx medications for the purposes of continued treatment – if the receipt was for the pharmacist or his family. It is expected now that there will be more regulations that will strengthen the pharmacist competencies, and the patient-centered approach could finally become common practice rather than just a professional aspiration.

Therefore, the present study examines the attitudes of future health-related professionals to the contribution of community pharmacists regarding health promotion and optimization of patient pharmacotherapy. Although previous papers have examined the issues of pharmaceutical care in general (11-12), the current study focuses on a specific group of patients with unsatisfactory morbidity and mortality rates in Poland i.e. those with CVD diseases / or risk factors.

A survey was administered to the students of the Medical University of Lodz (Poland). The survey examined the attitudes of first-year and fifth-year Laboratory Medicine, Medicine, Pharmacy, and Nursing and Midwifery students toward the contribution of community pharmacists in the prevention of cardiovascular risk and diseases.

Table 1. The overview of the competencies of community pharmacists in example countries.

| Item                          | Poland# | US          | Canada                  | Portugal                                             | France                   | Great Britain          |
|-------------------------------|---------|-------------|-------------------------|------------------------------------------------------|--------------------------|------------------------|
| Vaccination                   | No      | Yes         | Yes - influenza in most provinces | Yes - vaccinations not included in the immunization schedule | Yes - influenza         | Yes - influenza        |
| Identification and evaluation of DRPs | No      | Yes         | Yes                     | Yes                                                  | Yes                      | Yes                    |
| BP measurements               | No      | Yes         | Yes                     | Yes                                                  | Yes                      | Yes                    |
| Blood glucose measurements    | No      | Yes         | Yes, in some provinces  | Yes                                                  | Yes                      | Depending on local regulations |
| Blood lipid measurements      | No      | Yes         | No                      | Yes                                                  | No                       | No                     |
| BMI monitoring                | No      | No data     | Yes, in some provinces  | Yes                                                  | Yes                      | Yes                    |
| Smoking cessation             | No      | Yes         | Yes                     | Yes                                                  | Yes                      | Yes                    |
| Access to patient medical documentation | No      | Yes, concerns some parts of documentation | Yes, in some provinces | Yes, concerns some parts of documentation | Yes, concerns some parts of documentation | Yes, concerns some parts of documentation |
| Prescription of Rx drug       | Yes, in case of patient’s health and life risk | Yes, but there can be differences among provinces | Yes, in some provinces | No data | Yes, in case of drug prolongation | Yes, concerns prescribing permissions of independent prescriber |
| Generic substitution          | Yes     | Yes, in some states | Yes, the medicines are prescribed according to INN system** | Yes, the medicines are prescribed according to INN system** | No                      | Yes, in some districts |
| New medicine service         | No      | Yes         | No                      | No                                                   | No                       | Yes                    |

*The following table presents only a few examples of countries where community pharmacists’ roles were extended, ** INN=International Nonproprietary Names, # before the entry into force of the act on the profession of pharmacist (Dz.U. 2021. 97). Based on (5-10).
The role of community pharmacists…

The first aim was to determine the construct validity and internal consistency of the self-administered questionnaire based on this proposed set of categories. In addition, to evaluate the preparedness for future collaboration with community pharmacists, the study examines the perception of community pharmacist activities by students, reviews the factor structure of the questionnaire, identifies trends visible between 1st and 5th-year students, and compares these with the basic knowledge of CVD risk factors among students. The findings will then be used to develop a more universally applicable tool to assess opinions about the particular activities of community pharmacists.

EXPERIMENTAL

Study design. This was an observational study carried out with students of the Faculty of Pharmacy at the Medical University of Lodz (Poland).

Data collection. The study sample included a group of first and fifth-year students of the following faculties: Laboratory Medicine, Medicine, Nursing and Midwifery, Pharmacy. The questionnaires were distributed in the classrooms (November 2019 – February 2020). After the researchers explained the study and guaranteed confidentiality and anonymity, the participants were asked to complete it. The researchers informed the students that their participation was voluntary and anonymous. The average time for completion was 30 min. Students were not allowed to look up answers during the survey. The participants were prevented from using mobile devices during the survey.

Instruments. The self-reporting questionnaire was provided in Polish, and was translated into English, and contained three sections. The first section consisted of six single-choice questions concerning socio-demographic variables: nationality, age, sex, place of residence, future career choices. The second section was a specific knowledge test that included fifteen multiple-choice questions about risk factors that increase the probability of CVD. The questions were chosen randomly. A three-member panel was appointed of experts from the area of pharmacotherapy and pharmaceutical care. They had relevant experience within education. The panel proposed a list of 30 common questions according to a review of present teaching standards for Laboratory Medicine, Medicine, Nursing and Midwifery, and Pharmacy, as well as existing European and national recommendations for the prevention of cardiovascular diseases. Any disagreements within the selection or interpretation of questions were resolved through verbal discussion with an independent researcher (M.J-S. or U.K). The third section was based on a 5-point Likert-like scale and included 24 statements about respondent attitudes toward the contribution of community pharmacists in the prevention of cardiovascular disease, according to current polish legislation and based on professional experience in other countries. The Likert Scale was proposed as it does not require the participant to provide a simple and concrete “yes or no” answer and does not force the participant to take a stand on a particular topic. The possible responses were arranged on a five-point scale ranging from “strongly disagree” (1 point) to “strongly agree” (5 points). The instrument was pre-tested on a sample of 20 students who were randomly selected from the target population in order to test the questions and decrease the risk of any misunderstanding or misinterpretation. The students who completed the pre-test were not included in the subsequent analysis.

Data analysis. The results were analyzed with STATISTICA 13 software. The responses addressed to section 3 were ranged from ‘strongly disagree’ – 1 point to ‘strongly agree’ – 5 points and were analyzed using principal component analysis (PCA). A randomly selected sample of 248 cases (approximately one-third of all) was subjected to validation of the 5-point Likert scale. Equamax rotation was used to determine the scale factors. The Likert-like scale was modified by assessing the loadings and removing any unnecessary or redundant items. Cronbach’s alpha was calculated to determine the scale’s reliability according to each factor, separately. The Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy and Bartlett’s test of sphericity were used to verify the hypothesis that the correlation matrix is an identity matrix. Confirmatory item analysis (CIA) was then used to evaluate the goodness of fit of the statistical model to the modified Likert-like scale by calculating the Root Mean Square Error of Approximation (RMSEA) and Goodness of Fit Indices (GFI). The chi-square test was used to test the statistical significance of differences among subgroups of participants (faculty or year of the study) with regard to the frequency distribution of categorical demographic variables (section 1). The non-parametric Mann Whitney U-test or Kruskal-Wallis test was used to compare the mean ranks from section 2, where the questions were coded as 1 (right answer) or 0 (wrong answer), and section 3 (one to five point Likert scale) in one-factor analysis. Finally, the principal component analysis (PCA) was used to calculate factor scores. The Kruskal-Wallis test was used to compare the subgroups (faculty or study year), according to obtained
factor scores. The correlations between the overall score in the knowledge test – calculated as the ratio of the number of correct answers to all – and factor loadings were assessed using the non-parametric Spearman test.

A p-value of less than 0.05 was considered statistically significant.

RESULTS

Demographic profile of respondents
A total of 1907 students took the survey and 854 responded (a 45% response rate). More than 90 percent of responses were obtained from Pharmacy (94.6%) and Laboratory Medicine (100%) faculties. The questionnaires were completed by 54.6% of future nurses and by 31.8% of Medicine students, adequately. Such differences at least partially result from disproportions in the number of students of particular faculties at the Medical University of Lodz; e.g. there were more than 1300 of 1st and 5th year Medicine students, and only sixty future diagnostics (both 1st and 5th-year study) in the year of completing the survey. The majority of applicants who responded were female, both for the year 1 and 5 as well as for four faculties; the lowest percentage (64-65%) was observed in the Faculty of Medicine. No significant relationship was found between gender ratio and study year (Table 2). Regarding the preferred place of future employment, significant variation was found with regard to faculty and study year (\( P < 0.0001; \) chi-square test). The 5th year students were more decided according to their professional plans, e.g. the majority of medical students or

| Demographic characteristics | Laboratory medicine | Total |
|-----------------------------|----------------------|-------|
| **Study year**              | 1\textsuperscript{st} | 5\textsuperscript{th} |
| Number of participants (%)  | 41 (66.1)            | 21 (33.9) |
| Age (median)                | 19 (19)              | 23 (23)  |
| Female (%)                  | 36 (87.5)            | 18 (85.7) |
| Nationality (%)             |                      |        |
| Polish                      | 41 (100)             | 21 (100) |
| Place of origin (%)         | 13 (31.7)            | 8 (38.1) |
| Village                     | 9 (21.9)             | 7 (33.3) |
| City of < 50 000 inhabitants| 7 (17.1)             | 3 (14.3) |
| City of 50 000 to 500 000 inhabitants | 12 (29.3) | 3 (14.3) |
| City of > 500 000 inhabitants| 222 (84.1)           | 153 (95.6) |
| Place of origin (%)         | 54 (20.4)            | 25 (15.6) |
| Village                     | 41 (15.5)            | 25 (15.6) |
| City of < 50 000 inhabitants| 68 (25.7)            | 30 (18.7) |
| City of 50 000 to 500 000 inhabitants | 101 (38.3) | 80 (50.0) |
| City of > 500 000 inhabitants| 113 (73.4)           | 65 (98.5) |
| Nationality (%)             | 154 (70.0)           | 66 (30.0) |
| Place of origin (%)         | 19 (19)              | 23 (24)  |
| Village                     | 65 (42.2)            | 16 (24.2) |
| City of < 50 000 inhabitants| 27 (17.5)            | 9 (13.6) |
| City of 50 000 to 500 000 inhabitants | 30 (19.5) | 10 (15.2) |
| City of > 500 000 inhabitants| 32 (20.8)            | 31 (47.0) |

Table 2. Characteristics of respondents according to the faculty and year of study (N = 854).
Table 2. Characteristics of respondents according to the faculty and year of study (N = 854); cont.

| Demographic characteristics | Faculty Nursing and Midwifery | Nursing and Midwifery |
|-----------------------------|-------------------------------|------------------------|
| Number of participants (%)  | 99 (66.9)                     | 49 (34.1)              |
| Age (median)                | 19 (19, 20)                   | 24 (23, 25)            |
| Female (%) a                | 92 (92.9)                     | 47 (95.9)              |
| Nationality (%)             |                               |                        |
| Polish                      | 98 (98.9)                     | 49 (100)               |
| Place of origin (%)         |                               |                        |
| Village                     | 58 (58.6)                     | 10 (20.4)              |
| City of <50 000 inhabitants | 16 (16.2)                     | 2 (4.8)                |
| City of 50 000 to 500 000 inhabitants | 11 (11.1) | 9 (18.4) |
| City of > 500 000 inhabitants | 14 (14.2)  | 28 (57.2) |

Professional Plans

| Faculty a, b | Laboratory Medicine |
|--------------|---------------------|
| Hospital     | 9 (21.9)            |
| Community pharmacy | -               |
| Hospital pharmacy | -              |
| University   | 9 (21.9)            |
| Pharmaceutical Industry | 2 (4.9)     |
| Diagnostic Laboratory Service | 10 (24.4) |
| Community Health Centre | -          |
| Sanitary-epidemiological station | 1 (2.4)     |
| Blood Donation Centre | 5 (12.2)    |
| I do not know | 5 (12.2)            |

| Faculty a, b | Pharmacy |
|--------------|----------|
| Hospital     | 175 (66.3) |
| Community pharmacy | 1 (0.4)   |
| Hospital pharmacy | -         |
| University   | 11 (4.2)  |
| Pharmaceutical Industry | 2 (0.7)   |
| Diagnostic Laboratory Service | 1 (0.4)   |
| Sanitary-epidemiological station | -         |
| Community Health Centre | 50 (18.9) |
| Blood Donation Centre | 1 (0.4)   |
| I do not know | 23 (8.7)  |

| Faculty a, b | Nursing and Midwifery |
|--------------|-----------------------|
| Hospital     | 75 (75.7)             |
| Community pharmacy | -          |
| Hospital pharmacy | -            |
| University   | 1 (1.0)               |
| Pharmaceutical Industry | -         |
| Diagnostic Laboratory Service | 3 (1.9)   |
| Sanitary-epidemiological station | -         |
| Community Health Centre | 15 (15.1) |
| Blood Donation Centre | 2 (2.0)   |
| I do not know | 6 (6.0)               |

aP < 0.0001 Chi-Square Test – First variable: Faculty and second variable: Preferred place of future employment;
bP < 0.0001 Chi-Square Test – First variable: Year of the study and second variable: Preferred place of future employment
Table 3. Questions ranked by mean percentage of corrected responses given by all students.

| No | Question                                                                                                                                                                                                 | Correct answers N (%) |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| 8  | Prevention of CVD involves improving risk factors through lifestyle interventions such as smoking cessation. The right answer is: ☑ Smoking can be associated with higher BP levels or resting heart rate; ☐ Deleterious effects of passive smoking have not been confirmed, yet; ☐ Electronic cigarettes (e-cigarettes) are recommended tool for smoking cessation; ☐ Combining behavioral support with pharmacotherapy does not increase the success rate of smoking cessation | 782 (92.3)            |
| 1  | Prevention of cardiovascular disease can involve: ☐ Improving lifestyle in healthy people; ☐ Reducing risk factors in patients with established disease, eg. by optimization of pharmacotherapy; ☑ Screening tests; ☑ All of the above | 653 (77.1)            |
| 10 | Common causes of secondary hypertension are: ☐ Obstructive sleep apnea; ☐ Endocrine causes; ☖ Renovascular disease; ☑ All of the above                                                                                       | 594 (70.1)            |
| 5  | Low dose acetylsalicylic acid (aspirin) is: ☐ Recommended for all hypertensive patients; ☑ Recommended for secondary prevention of cardiovascular diseases; ☑ Recommended for all patients with diabetes mellitus (DM); ☐ Not associated with major bleeding risk when it is administered chronically | 577 (68.1)            |
| 13 | Global cardiovascular risk assessment considers such factors as: ☐ Organ damage; ☑ Metabolic disorders; ☑ Cardiovascular and renal disease; ☑ All of the above                                                                 | 570 (67.3)            |
| 15 | Treatment targets for the management of diabetes type 2, in order to reduce moderate cardiovascular risk and microangiopathy, can include: ☐ HbA1c < 7.0% (< 53 mmol/mol); ☐ LDL-C < 100 mg/dL (2.6 mmol/L); ☑ BP lowering < 130/80 mmHg; ☑ All of the above | 536 (63.2)            |
| 3  | Factors influencing cardiovascular risk in patients with hypertension can include: ☐ Smoking; ☐ Uric acid increased levels; ☑ Heart rate (resting values >80 beats/min); ☑ All of the above                                                                 | 529 (62.4)            |
| 4  | Several factors can raise the risk of having hypertension, with the exclusion of: ☑ Excessive weight gain (BMI > 25 kg/m²); ☐ Abdominal obesity; ☑ Waist circumference >102 cm in men and >88 cm in women; ☑ The body mass above 80 kg | 513 (60.5)            |
| 2  | According to present European guidelines for the management of arterial hypertension, hypertension (blood pressure is recorded as the average of the last two BP readings during at least two repeat visits) is defined as office BP values above: ☐ 140 mmHg (systolic blood pressure-SBP) and/or 85 mmHg (diastolic blood pressure-DBP); ☑ 135 mmHg (SBP) and/or 85 mmHg (DBP); ☑ 130 mmHg (SBP and/or 80 mmHg (DBP); ☑ 140 mmHg (SBP) and/or 90 mmHg (DBP) | 470 (55.5)            |
| 11 | Recommendations for pharmacological low-density lipoprotein cholesterol-lowering (statins) can include: ☐ Patients at high (or at very high) risk of a cardiovascular event; ☑ Primary prevention of cardiovascular events; ☑ Previous acute coronary syndrome; ☑ All of the above | 469 (55.4)            |
| 7  | The aim of treatment of arterial hypertension under the age of 65 is to reduce the increased blood pressure: ☑ to the value of 135 mmHg; ☐ to the value of 130 mmHg; ☑ less than 140 mmHg, and achieving the values >120 mmHg, if well-tolerated; ☑ BP thresholds are not defined if the treatment is well-tolerated | 311 (36.7)            |
| 9  | Regular physical activity may be beneficial for cardiovascular health. Hypertensive patients should be advised to participate in moderate intensity dynamic aerobic exercise (walking, jogging, cycling, or swimming) on at least: ☑ 5–7 days per week, in 15 min.; ☑ 3 days per week, in 30 min.; ☑ 5-7 days per week, in 30 min.; ☑ 5-7 days per week, in 60 min | 258 (30.4)            |
| 14 | Provided that the treatment is well tolerated, for people > 80 years, an SBP target range is: ☑ 140–150 mmHg; ☑ under 140 mmHg; ☑ under 130 mmHg; ☐ under 120 mmHg | 207 (24.4)            |
| 6  | For patients at very high risk (documented cardiovascular disease, incl. myocardial infarction or stroke, or SCORE>10%, or diabetes mellitus with target organ damage) a therapeutic regimen should achieve an LDL-C goal: ☐ Below 115 mg/dL (3 mmol/L); ☑ Below 100 mg/dL (2.5 mmol/L); ☑ Below 70 mg/dL (1.8 mmol/L); ☑ Below 55 mg/dL (1.4 mmol/L) | 134 (15.8)            |
| 12 | Deleterious impact on cardiovascular prognosis can have such factors as: ☑ Caffeine, as it increases risk of hypertension in case of regular consumption; ☑ High-fructose corn syrup due to risk of development of insulin resistance; ☑ Salt, and thereby salt substitutes that contain potassium chloride are recommended; ☑ All of the above | 102 (12.0)            |

☑ Correct answers; ☐ False answers that were given most often (At least one-third of all answers) (N = 854)
future nurses chose hospital work (78.7% and 96%, adequately), pharmacy students indicated on community pharmacy (57.6%), while future diagnosticians preferred Diagnostic Laboratory Centers or Blood Donation Centers. Detailed demographic characteristics and professional plans of study participants are presented in Table 2.

The knowledge test

A detailed list of questions ranged according to the percentage of correct answers is presented in Table 3. The highest percentage of correct answers was given by Medicine students: the median score was 60% with (50-70) IQR (P < 0.05). The fifth-year students were more likely to give correct answers than the first-year students (P < 0.0001) (Figure 1).

The evaluation of the 5-point Likert-like scale

The principal component analysis revealed five factors which accounted for 65.6% of the variance: 33.3% for ‘OTHER ACTIVITIES’ (5 items), 12.3% for ‘MEASUREMENTS’ (4 items), 8.8% for ‘EDUCATION’ (4 items), 6.7% for ‘DRPs’ (4 items), and 4.5% for ‘INTERVIEW’ (4 items). The following three out of twenty-four items were removed, as their loadings were less than 0.6: ‘For better medication adherence, the pharmacist should be given the opportunity to dispense less expensive generic drug’ (0.575); ‘(…) to monitor therapy persistence’ (0.542), and ‘The pharmacist should participate in optimization of pharmacotherapy for patients with cardiovascular diseases, by performing medication reviews and identification of drug-related problems and, if needed, sends to the physician (contacts the physician), in such cases as: None or incomplete drug treatment in spite of existing indication (accompanying with impaired glycemia, lipid profile or BP levels’ (0.469) (Table 4 and Table 5). Finally, a modified version of the scale consisting of 21 items was created. The Cronbach’s alpha was 0.861 after

| Question No | Factor | Item |
|-------------|--------|------|
| Q 1         | E1     | Smoking       |
| Q 2         | E2     | Lack of physical activity and/or obesity |
| Q 3         | E3     | Alcohol consumption |
| Q 4         | E4     | Lipid abnormalities such as hypercholesterolemia and hypertriglyceridemia |
| Q 5         | I1     | Performs interview and, if needed, gives patient advice on healthy eating (incl. sodium restriction and low-calorie diet) |
| Q 6         | I2     | Performs interview (incl. scoring the Fagerstrom Test for Nicotine Dependence) and, if needed, gives patient advice on smoking cessation (nicotine replacement therapy, other OTC medicaments) or sends to the physician |
| Q 7         | I3     | Performs interview and, if needed, gives patient advice on regular exercise, or sends to the physician |
| Q 8         | I4     | Performs interview and, if needed, gives patient advice on seasonal influenza vaccination |
modifications of the first factor, 0.851 of the second, 0.894 of the third, 0.879 of the fourth, and 0.873 of the fifth (Table 6). The KMO value was 0.883 and can be considered a good indication that principal component or factor analysis was suitable for studying these variables. The Bartlett test (chi-square 10027.9; P < 0.0001) indicated absence of an identity matrix. The goodness of fit of the statistical model to the modified Likert-like scale was confirmed by confirmatory item analysis: RMSEA < 0.08 (0.0733, 95% CI 0.069-0.078), GFI > 0.8 (0.916).

Confirmatory item analysis revealed any positive correlation among particular factors (> 0.3), with the most pronounced between ‘INTERVIEW’ and ‘EDUCATION’ (0.606); ‘INTERVIEW’ and ‘MEASUREMENTS’ (0.632) or ‘DRPS’ and ‘OTHER ACTIVITIES’ (0.459).

**Attitude toward the role of the community pharmacist in the prevention of CVD**

Figures 2 and 3 demonstrate discrepancies in opinions, expressed as factor scores, among Medicine, Pharmacy, Laboratory Medicine, and Nursing students, as well as 1st and 5th-year students. The significant differences among faculties were revealed for such factors as ‘OTHER ACTIVITIES’.
Table 5. Principal Component Analysis (PCA) Loadings – Modified Scale.

| Category                              | Item                                                                 | Factor 1 – Activities | Factor 2 – Measurements | Factor 3 – Education | Factor 4 – Dealing with DRP(s) | Factor 5 – Interview |
|---------------------------------------|----------------------------------------------------------------------|-----------------------|-------------------------|----------------------|-------------------------------|----------------------|
| E1 Education of patients according to CVD risk factors as:                | Smoking                                                             | 0.033                 | 0.121                   | 0.861                | 0.156                         | 0.058                |
|                                       | Lack of PA and/or obesity                                           | 0.032                 | 0.102                   | 0.892                | 0.041                         | 0.127                |
| E3 Alcohol consumption                |                                                                     | 0.095                 | 0.064                   | 0.844                | 0.110                         | 0.154                |
| E4 High TC and TG                    |                                                                     | 0.240                 | 0.103                   | 0.755                | 0.156                         | 0.112                |
| I1 Healthy eating                    |                                                                     | 0.092                 | 0.280                   | 0.477                | 0.018                         | 0.618                |
| I2 Smoking cessation                 |                                                                     | 0.128                 | 0.360                   | 0.320                | 0.243                         | 0.689                |
| I3 Regular exercise                  |                                                                     | 0.134                 | 0.347                   | 0.391                | 0.129                         | 0.706                |
| I4 Seasonal influenza vaccination     |                                                                     | 0.140                 | 0.251                   | 0.095                | 0.283                         | 0.716                |
| M1 Control of CVD risk factors, by:  | Measurement of body weight                                         | 0.066                 | 0.751                   | 0.266                | -0.037                        | 0.178                |
| M2 Evaluation of BP levels           |                                                                     | 0.161                 | 0.789                   | 0.095                | 0.195                         | 0.186                |
| M3 Vaccination of high-risk patients against influenza | Measurement and evaluation of glycaemia | 0.141 | 0.868 | 0.125 | 0.148 | 0.074 |
| M4 Vaccination of high-risk patients against influenza | Vaccination of high-risk patients against influenza | 0.079 | 0.727 | -0.015 | 0.071 | 0.157 |
| P1 Inappropriate duplication of therapeutic group or active ingredient    |                                                                     | 0.207                 | 0.177                   | 0.051                | 0.851                         | 0.051                |
| P2 Concurrent administration of drug and alcohol or tobacco               |                                                                     | 0.105                 | 0.071                   | 0.137                | 0.832                         | 0.197                |
| P3 Dispensing less expensive generic drug                                  |                                                                     | 0.346                 | -0.077                  | 0.125                | 0.689                         | 0.094                |
| P4 Monitoring of therapy persistence |                                                                     | 0.079                 | -0.0822                 | 0.046                | -0.011                        | 0.179                |
| P5 Drug treatment in spite of existing indication                          |                                                                     | 0.433                 | 0.314                   | 0.161                | 0.469                         | -0.0178              |
| A1 Access the medical information about patient                            |                                                                     | 0.184                 | 0.0803                  | 0.254                | -0.048                        |                     |
| A2 Access the selected patient outcomes (ABPM, lipid profile, glycaemia)  |                                                                     | 0.728                 | 0.198                   | 0.083                | 0.255                         | -0.118               |
| A3 Prescription of therapeutic agent (Rx)                                   |                                                                     | 0.790                 | -0.0822                 | 0.046                | -0.011                        | 0.179                |
| A4 Modification of drug doses and therapeutic regimens                     |                                                                     | 0.825                 | 0.106                   | -0.040               | -0.075                        | 0.120                |
| A5 Change of drug formulation                                               |                                                                     | 0.542                 | 0.246                   | 0.157                | 0.268                         | -0.087               |

ABPM = Ambulatory Blood Pressure Monitoring; CVD = Cardiovascular Disease; DRP = Drug Related Problem; TC = Total Cholesterol; TG = Triglycerides; PA = Physical Activity (N = 248).
The particular items that made up these factors were more approved by pharmacy students (Figure 2). Fifth year students tended to be more positive than first years in relation to factor 3 (P = 0.0022) and factor 4 (P = 0.0002) and more negative in relation to factor 1 (P = 0.0013).

Regarding the options rather agree and strongly agree, the top activities, that were approved most, concerning information given to patients about proper drug administration and storage (factor P5) with the responses ranging from 77.0 to 93.6% according to the faculty; education about such risk factors as smoking (E1) ranged from 71.0-87.7%; high lipid levels (E4) ranged from 72.6-86.8% of responses; identification of DRPs related to concurrent administration of drug and alcohol or tobacco (P2) ranged from 74.2-87.2% of responses. Managing with DRPs related to drug-drug interactions (P3) was also highlighted by future medicine doctors, diagnosticians, and especially pharmacists (72.5-83.9% of responses) and less by future nurses and midwives (69.6%).

For all the items that were classified to the category ‘DRPs’, significant differences were denoted between the last two subgroups of students (P < 0.05). The less preferable were prescription of therapeutic agent, when justified (A3), modification of drug doses and therapeutic regimens (A4), or change of drug formulation (A5). In this case, the responses: rather disagree and strongly disagree were given by 25.1-45.2% of Laboratory Medicine, Medicine or Nursing students. Also, every fifth student was against the pharmacists’ access to patient medical documentation (A1) and clinical/laboratory findings (ABPM, lipid profile, glycemia) (A2). However, a higher percentage of future pharmacists (P < 0.00001) than students of other faculties considered all mentioned (A1-A5) items as important activities for CVD risk prevention. There were no discrepancies among faculties as regards attitude toward such particular items as measurements.

Table 6. Item-total correlations and Cronbach’s coefficient alphas resulting after confirmatory Item Analysis (CIA) and Model Re-Specification (N = 248).

| Factor | Item | Primary scale | Modified scale |
|--------|------|---------------|----------------|
|        |      | Item-total correlation | Cronbach’s alpha | Item-total correlation | Cronbach’s alpha if item deleted | Cronbach’s alpha | Cronbach’s alpha if item deleted |
| Factor 1 – Activities | A1 | 0.719 | 0.845 | 0.695 | 0.828 |
|        | A2 | 0.708 | 0.792 | 0.684 | 0.831 |
|        | A3 | 0.639 | 0.822 | 0.672 | 0.834 |
|        | A4 | 0.662 | 0.812 | 0.718 | 0.822 |
|        | A5 | - | - | 0.627 | 0.845 |
| Factor 2 – Measurements | M1 | 0.650 | 0.851 | 0.650 | 0.828 |
|        | M2 | 0.759 | 0.785 | 0.759 | 0.785 |
|        | M3 | 0.796 | 0.765 | 0.796 | 0.765 |
|        | M4 | 0.579 | 0.861 | 0.579 | 0.861 |
| Factor 3 – Education | E1 | 0.804 | 0.894 | 0.804 | 0.853 |
|        | E2 | 0.812 | 0.849 | 0.812 | 0.849 |
|        | E3 | 0.779 | 0.859 | 0.779 | 0.859 |
|        | E4 | 0.689 | 0.891 | 0.689 | 0.891 |
| Factor 4 – Dealing with DRPs(s) | P1 | 0.783 | 0.855 | 0.822 | 0.879 | 0.810 |
|        | P2 | 0.693 | 0.820 | 0.761 | 0.835 |
|        | P3 | 0.815 | 0.769 | 0.770 | 0.832 |
|        | P4 | 0.543 | 0.891 | - | - |
|        | P5 | - | - | 0.606 | 0.891 |
| Factor 5 – Interview | I1 | 0.694 | 0.873 | 0.853 | 0.853 |
|        | I2 | 0.798 | 0.811 | 0.798 | 0.811 |
|        | I3 | 0.842 | 0.792 | 0.842 | 0.792 |
|        | I4 | 0.595 | 0.888 | 0.595 | 0.888 |

# P < 0.0001

(factor 1; P < 0.0001), ‘EDUCATION’(factor 3; P = 0.0109), ‘DRPs’ (factor 4; P < 0.0001). The particular items that made up these factors were more approved by pharmacy students (Figure 2).
(BP, glycemia) and vaccinations (M1-M4) as well as performing interview (I1-I4). Similarly, no significant differences were found for factors that were attributed to the above items in factor analysis.

No significant positive correlations \( (P < 0.05) \) were found between the summarized score for the knowledge test and loading factors, i.e. factor 1 (OTHER ACTIVITIES), factor 3 (EDUCATION), and factor 4 (DRPs).

The willingness to take common classes with other faculties of Medical University was expressed significantly more by future pharmacists \( (P < 0.0001) \) as compared to other respondents. The percentage of positive answers (agree or strongly agree) exceeded 75% for pharmacy students, 55% – medicine students, 50% – future nurses, and only 40% – diagnosticians. There were no discrepancies in such expectations according to the study year.

Figure 2. Attitudes toward community pharmacists’ contribution in prevention of cardiovascular diseases according to the faculty – with increased factor loadings (Principal component analysis – PCA) the opinions were more positive – Kruskal-Wallis \( (3, N = 847) \), (a) Factor 1: \( H = 107.57; P < 0.0001 \), (b) Factor 2: \( H = 6.29; P = 0.10 \), (c) Factor 3: \( H = 11.16; P = 0.0109 \), (d) Factor 4: \( H = 44.29; P < 0.0001 \), (e) Factor 5: \( H = 0.97; P = 0.81 \).
The students who gave their positive opinion about such community pharmacists' competencies as access to medical/diagnostic data about a patient, modification of drug doses, or formulation (A1-A5) were more interested in inter-faculty courses on selected issues of pharmacotherapy; \( R \) (Spearman) > 0.3, \( P < 0.05 \).

Demographic characteristics of respondents incl. place of residence did not determine their opinions about the role of the pharmacist.
DISCUSSION AND CONCLUSION

The activities of community pharmacists in relation to their patients with CVD risk or disease focus on patient education and counseling as well as optimization of pharmacotherapy. There is hence a constant need for updating interdisciplinary knowledge according to current international guidelines. In the present study, older students of all the faculties had better knowledge about risk factors for CVD than younger students who had not had lessons in epidemiology or pharmacotherapy. A surprisingly low number of students (less than 40 percent) were familiar with actual recommended BP levels according to patient age or LDL-C goals for hypolipidemic therapy. Also, the awareness about dealing with modified CVD risk factors (diet, physical activity) seemed to be insufficient. Similar results were obtained by other authors, who found student knowledge of international guidelines to be unsatisfactory (13). However, more than 90% of students were familiar with the problem of smoking and recommended tools for smoking cessation.

Next in the current survey, the participants were asked to refer to several proposals of community pharmacists activity when managing CVD patients. According to the common definition of pharmaceutical care (3), the pharmacist is expected to work in concert with the patient’s other healthcare providers; hence the current survey was introduced not only to the future physicians but also to nurses and diagnosticians. Validation of the self-administered questionnaire based on a Likert-like scale displayed acceptable construct validity and internal consistency. The questionnaire comprised five factors that could describe such activity, all of which demonstrated good internal consistency. Particularly, the top activities that were indicated by respondents included information given to patients about proper drug administration and storage, education about such risk factors as smoking and high lipid levels, or identification of DRPs related to concurrent administration of drug and alcohol or tobacco. These items were awarded the highest approval, independently of study faculty, and seem to be well-known from the ordinary practice of community pharmacists. In general, any significant discrepancies among students were not provoked by items that could be classified to categories: ‘INTERVIEW’ (and giving advice according to lifestyle modifications) or ‘MEASUREMENTS’ (BP, glycemia, lipids). The examples of proposed actions included in the survey have been included in novel polish law regulations concerning the profession of pharmacist; e.g. evaluations of BP, glycemia, lipid parameters, or vaccinations against influenza. The final item has been the subject of much debate, but without clear recommendations. The question of the contribution of the community pharmacist into immunization may arise with the development of a vaccine against SARS-CoV-2. Significant differences were found among respondents with regard to dealing with drug-related problems and widely understood optimization of pharmacotherapy. In Poland, like in most industrialized countries, the population has been aging; this has led to an increased health care burden coupled with the use of many medications (Rx, OTC) by patients. Medication reviews have been proposed as a useful tool in order to manage this situation. For several years, during their curriculum, Pharmacy students have been taking part in classes where they can acquire skills according to the identification of DRPs (14). So it is not surprising that such service has achieved a great acceptance of this subgroup of respondents. Managing with DRPs

Figure 4. The willingness to take part in inter-faculty courses. The results are demonstrates as median of responses according to five-point Likert scale – Kruskal-Wallis (N = 847), according to the faculty – H = 44.9; P < 0.0001 (a) and year of the study – H = 2.5; P =0.1146 (b).
related to drug-food, or drug-drug interactions was also approved by future medicine doctors and diagnosticians, and less by future nurses and midwives. The category that strongly divided the respondents was access to the information about patient medical history and prescribed medications, patient outcomes as well as the opportunity to prescribe Rx medication, modification of dosage schedule or drug formulation (‘OTHER ACTIVITIES’). Again, the pharmacy students presented a more positive attitude to the proposed services. Current pharmaceutical care models – also these considered in novel Polish regulations – suggest that pharmacists could perform medication reviews in order to evaluate the drug-related problems, and then develop patient care plans and monitoring. Such a service would make drug therapy more effective and safe for individual patients but it requires a strong communication link between the physician and the pharmacist, as well as more detailed knowledge about patient history than could be obtained during a conversation with the patient. Community-based information systems would facilitate the exchange of information between pharmacists and other members of the health care team. In Poland, from January 2020 physicians are obliged to prescribe the medicines to the patient using electronic prescriptions. The E-prescription is saved on the Patient’s Internet Account, and the electronic record is transferred via a system from a doctor to a pharmacist, and from there to the institution that reimburses a given drug. Access to more detailed data about the patient, than only a single record containing the current prescription, is theoretically possible but no further action has yet been taken by the Polish authorities.

A patient-centered approach requires the pharmacist to work in collaboration with other health care providers. This would enable the pharmacist to monitor, initiate, and modify medication use as well as to prevent or identify and solve drug-related problems during medication reviews. Some authors report fewer barriers and fewer difficulties in contact with general practitioners when the pharmacists were employed in rural and provincial regions. In this case, the long-lasting relationships with local physicians were mostly characterized by mutual trust and appreciation (15). However, in the current survey, the attitudes toward the role of community pharmacists did not differ when considering students from urban and rural areas, separately.

Such interprofessional collaboration between pharmacists and other health care providers, especially with physicians, would enhance the advisory role of the pharmacist. Participation in interfaculty meetings and direct relationships among health care providers would create favorable conditions for such collaboration through the interchange of opinions and information and could convince about mutual competencies (15). For better results, this process should start at the university level from interprofessional education (16).

Our results suggest that student expectations of the pharmacist’s role did not evolve much over the course. The 5th year student opinions have become more positive in only two out of five factors that could define several activities in community pharmacy (‘EDUCATION’ and ‘DRPs’). It can be suggested that the attitudes of particular groups of future health care providers, due to lack of adequate courses, are influenced mainly by common society opinions. The student gaining knowledge about cardiovascular risk also had a moderate impact on his choices. The respondents who have achieved a better score in the test tended to demonstrate greater approval of the role of the pharmacist in patient education or dealing with DRPs, as well as access to medical data about the patient and the opportunity to change drug formulation or dosage schedules.

However, the willingness to take common classes with other faculties was expressed significantly more by future pharmacists (more than 70% of answers being agree or strongly agree). It can be hypothesized that a lack of interest in interfaculty courses would result in a future lack of cooperation after graduating. Interestingly, the students who were more interested in inter-faculty courses gave a positive opinion about such community pharmacist competencies as access to medical/diagnostic data about the patient, modification of drug doses, or formulation. Similar results were obtained by Piecuch et al. (2014) (16). The concept of pharmaceutical care was more prevalent for medical students who reported having more frequent relationships with pharmacy students, students who reported having scientific relationships, and students who participated in community services together with pharmacy students. More than seventy percent of medical students claimed that they do not consider themselves prepared for future collaboration with pharmacists.

Another point is that while future diagnosticians, nurses, and medicine doctors were constant in their choices of the future professional carrier, some discrepancies can be noticed in the case of future pharmacists. In our previous work, a similar trend was observed with 5th-year students favoring pharmacy work and 1st-year students – the pharmaceutical industry. The conclusion was that after the
5-year course, students are not convinced about the opportunity to achieve job development in the areas outside that of the community pharmacy. This in turn might emphasize the constant need to focus on more practical specialized knowledge and skills through the Curriculum, which also considers the variety of modern applications available in pharmaceutical science (17).

The question about a patient with CVD risk/disease has become the starting point to a more universal discussion on community pharmacists’ competencies in the area of pharmaceutical care. Our results indicate that future medicine doctors, diagnosticians, and nurses have an unclear picture of pharmacists as a health care profession. There are numerous reasons for that, including novel law regulations as well as a gap in the teaching of future health care providers. From the pharmacists’ view, there can be a lack of time or insufficient communication skills, as well as a requirement for actual knowledge about advanced pharmacology, pharmacotherapy, and drug interactions (18). It also cannot be excluded that some community pharmacists avoid interprofessional contact and delegate responsibility for patient safety to the patient himself (19). In the present survey, we focus only on the single aspect – medical education, changes of which should be accompanied by up-to-date law regulations. It can be suggested that such Curriculum updates would enable future collaboration of health care providers with community pharmacists who could go beyond dispensing of medicines and giving information related to proper usage and storage after the legal provisions extending pharmacist’s rights come into force. In details,

- The validated self-administered questionnaire comprising five factors displayed acceptable construct validity and internal consistency and therefore can be proposed as an example tool to assess the particular activities of community pharmacists in the pharmaceutical area.
- There is a need to design effective interprofessional workshops and activities aimed at increasing future health care providers’ awareness of areas where a pharmacist can, or should, be more engaged.
- The interfaculty classes could be the starting point for collaboration among members of particular medical professions, in the future.

Limitations of the study

The sample of size (N = 847) was sufficient for the validation of the Likert-like scale – 35.3 cases per item (40.3 cases per item – after deletion of 3 items). Secondly, while our findings refer to the Polish pharmaceutical market, they closely resemble the findings of other researchers who indicate difficulties and barriers to strengthen pharmaceutical service in their countries. In this context, the obtained results may be universal. Another limitation is that due to lack of data the comparison of demographic characteristics of respondents and non-respondents was not performed. A 5-point Likert Scale was used rather than a 7-point scale, as it was reported to be less confusing, readily comprehensible to respondents and better enabled them to express their views. Another limitation concerns the limited number of questions included in part two of the questionnaire. The present survey did not aim to test student knowledge in the area of cardiovascular risk and diseases in detail but rather the obtained result was to be another factor to correlate with the evaluated attitudes toward proposed community pharmacist activities. Finally, as the respondents were students at Medical University, their opinions may not reflect those of their older colleagues, but the study concerned aspects of medical education that in some way impacts the future attitudes of professional health care providers.

Conflict of interest

The authors report no conflicts of interest.

REFERENCES

1. https://ec.europa.eu/eurostat/statistics-explained/pdfscache/37359.pdf (accessed on 15.05.2020).
2. Zolezzi M., Abdallah O., Kheir N., Abdelsalam A.G.: Res. Social. Adm. Pharm. 15, 252 (2019).
3. Hepler C.D., Strand L.M.: Am. J. Hosp. Pharm. 47, 533 (1990).
4. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20210000097 (accessed on 16.01.2021).
5. https://www.pgeu.eu/wp-content/uploads/2019/04/PGEU-AR-2017-WEB.pdf (accessed on 15.05.2020).
6. Bach A.T., Goad J.A.: Integr. Pharm. Res. Pract. 4, 67 (2015).
7. Yuan C., Ding Y., Zhou K., Huang Y., Xi X.: Health Soc. Care Community 27, e567 (2019).
8. Song Y., Barthold D.: Health Econ. 27, 1717 (2018).
9. Sousa Pinto G., Bader L., Billberg K., Criddle D., Duggan C., et al.: Res. Social Adm. Pharm. 16, 974 (2020).
10. Sng Y., Ong C.K., Lai Y.F.: Eur. J. Hosp. Pharm. 26, 157 (2019).
11. Blondal A.B., Jonsson J.S., Sporrong S.K., Almarsdottir A.B.: Int. J. Clin. Pharm. 39, 945 (2017).
12. Świecekowski D., Merks P., Jaguszewski M., Siłuk D.: Acta Pol Pharm 74, 1021 (2017).
13. Maksimović M.Ž., Marinković J.M., Vlajinac H.D., Maksimović J.M., Tomanić M.S., et al.: Wien. Klin. Wochenschr. 129, 458 (2017).
14. Adams A.J., Weaver K.K.: Ann. Pharmacother. 50, 778 (2016).
15. Löffler C., Koudmani C., Böhmer F., Paschka S.D., Höck J., et al.: BMC Health Serv. Res. 17, 7 pages (2017).

© 2021 by Polish Pharmaceutical Society. This is an open-access article under the CC BY NC license (http://creativecommons.org/licenses/BY/4.0/).